Get started
Author

Marianna Tudini

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
2019 · Alessio Cortellini, Melissa Bersanelli, et al. · Journal for ImmunoTherapy of Cancer · 413
PDF
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
2009 · G. Di Lorenzo, R. Autorino, et al. · Annals of Oncology · 209
PDF
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
2019 · Alessio Cortellini, Sebastiano Buti, et al. · The Oncologist · 208
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
2019 · Alessio Cortellini, Rita Chiari, et al. · Clinical Lung Cancer · 181
Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
2009 · Giuseppe Di Lorenzo, Giacomo Cartenì, et al. · Journal of Clinical Oncology · 131
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
2020 · Alessio Cortellini, Melissa Bersanelli, et al. · European Journal of Cancer · 128
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
2020 · Alessio Cortellini, Marcello Tiseo, et al. · Cancer Immunology Immunotherapy · 99
PDF
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
2018 · Sabino De Placido, Ciro Gallo, et al. · The Lancet Oncology · 93
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
2020 · Alessio Cortellini, Alex Friedlaender, et al. · Clinical Lung Cancer · 87
PDF
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
2020 · Olga Nigro, Graziella Pinotti, et al. · European Journal of Cancer · 74
PDF
Efficacy of Pregabalin in the Management of Cetuximab-Related Itch
2006 · Giampiero Porzio, Federica Aielli, et al. · Journal of Pain and Symptom Management · 53
PDF
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study
2010 · Gemma Bruera, Alessandra Santomaggio, et al. · BMC Cancer · 46
PDF
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
2019 · Alessio Cortellini, Maria G. Vitale, et al. · Journal of Translational Medicine · 29
PDF
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
2023 · Martina Catalano, Sara Elena Rebuzzi, et al. · JAMA Network Open · 17
PDF
Care strategies and therapeutic pathways for chronic pain patients in Abruzzo Region, Italy.
2017 · C Leuter, A Piroli, et al. · PubMed · 14
PDF
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study
2020 · Alessio Cortellini, Sebastiano Buti, et al. · OncoImmunology · 12
PDF
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study
2024 · Martina Catalano, Sara Elena Rebuzzi, et al. · Frontiers in Immunology · 9
PDF
Effective Analgesic Score: A “Marker” of the Effects of Chemotherapy on Pain in Advanced Cancer Patients?
2007 · Giampiero Porzio, Federica Aielli, et al. · Journal of Pain and Symptom Management · 5
PDF
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study
2024 · Veronica Murianni, Alessio Signori, et al. · Frontiers in Oncology · 4
PDF
Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient
2015 · Marta Gubbiotti, Barbara Pistilli, et al. · Future Oncology · 4
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study
2024 · Brigida Anna Maiorano, Martina Catalano, et al. · Clinical Genitourinary Cancer · 3
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study
2024 · Shobana Anpalakhan, Giuseppe Luigi Banna, et al. · Immunotherapy · 3
PDF
“Poker” schedule of weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIR-B/FOX) in advanced colorectal cancer: A phase II study
2009 · A. Santomaggio, E. Ricevuto, et al. · Journal of Clinical Oncology · 3
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study
2026 · Francesco Pantano, Andrea Malgeri, et al. · Frontiers in Oncology · 1
PDF
Hepatic sinusoidal obstruction syndrome (SOS) associated with checkpoint inhibitor therapy
2024 · Marianna Litterio, Nicole Marchetti, et al. · European Journal of Case Reports in Internal Medicine · 1
PDF
Works count: 43
Citation count: 1,832
H-index: 14
I10-index: 16
Year
Topic
Type